Cathie Wood's ARK Invest Shifts Focus: Sells Tesla, Bets Big on AI with Tempus

Cathie Wood's ARK trades Tesla, Coinbase, and Buys Tempus Stock By Investing.com

Cathie Wood's ARK ETF published their daily trades for Wednesday, December 18th, 2024, revealing significant activity across a range of holdings. The largest dollar-value trade came from the sale of Tesla Inc (NASDAQ:TSLA) shares, with ARK parting with 20,582 shares for a total value of approximately $9.9 million. This sale continues a recent trend for ARK, which has been reducing its Tesla holdings over the past week. In contrast, ARK showed a growing interest in Tempus AI Inc (NYSE:TEM), acquiring 335,664 shares valued at around $13.1 million. This follows a consistent pattern of buying into Tempus AI, indicating a strong conviction in the company's prospects. ARK also executed a significant sale of Coinbase Global Inc (NASDAQ:COIN), offloading 13,780 shares with a total value of nearly $4.3 million. This move comes amidst a backdrop of fluctuating sentiment in the cryptocurrency market, which may have influenced ARK's decision to reduce its position. On the buying front, ARK increased its stake in Futu Holdings Ltd (NASDAQ:FUTU), purchasing 70,585 shares for approximately $6.1 million. This trade aligns with ARK's strategy of investing in innovative fintech companies. Another notable buy was Beam Therapeutics Inc (NASDAQ:BEAM), with ARK acquiring 116,119 shares across its ETFs, totaling a value of over $3.3 million. This investment suggests ARK's ongoing interest in cutting-edge biotech firms specializing in gene editing. Smaller but still significant trades included the purchase of shares in Pacific Biosciences (NASDAQ:PACB) of California Inc (NASDAQ:PACB), Personalis Inc (NASDAQ:PSNL), and Intellia Therapeutics Inc (NASDAQ:NTLA), as well as the sale of Adaptive Biotechnologies Corp (NASDAQ:ADPT), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Shopify Inc (NYSE:NYSE:SHOP), and Veeva Systems Inc (NYSE:NYSE:VEEV). Overall, ARK's trades for the day reflect a strategic balance between taking profits in certain holdings and reinforcing positions in companies that align with their investment thesis on innovation and disruptive technology. Investors following ARK's movements will note the ETF's continued focus on genomic and biotech stocks, alongside a cautious approach to more volatile sectors like cryptocurrency.

Cathie Wood's ARK sells Tesla, buys Tempus AI stock By Investing.com

Cathie Wood's ARK ETF published their daily trades for Thursday, December 12th, 2024, revealing a series of strategic moves within its portfolio. Topping the list in terms of dollar value, ARK's ARKK ETF sold 51,335 shares of Tesla Inc (NASDAQ:TSLA), amounting to a significant $21,805,567. This sale stands out as the most substantial trade of the day, reflecting ARK's latest adjustment in its position on the electric vehicle giant. On the flip side, ARK showed a growing interest in Tempus AI Inc (TEM), with a combined purchase of 424,522 shares across its ARKK and ARKG ETFs, totaling $18,335,104. This move indicates a bullish stance on the artificial intelligence company and marks a continuation of ARK's investment in the firm, following similar acquisitions earlier in the week. ARK also made a notable sale of 205,897 shares of Rocket Lab USA Inc (NASDAQ:RKLB) through its ARKQ ETF, totaling $4,807,695. This sell-off was closely followed by a purchase in the same ETF, acquiring 154,873 shares of Symbotic Inc (NASDAQ:SYM) for $4,132,011, reflecting a rebalancing towards the robotics automation company. Other sales included Adaptive Biotechnologies Corp (NASDAQ:ADPT) with 20,353 shares sold for $129,852, Veracyte Inc (NASDAQ:VCYT) shedding 31,181 shares at $1,356,685, and Veeva Systems Inc (NYSE:NYSE:VEEV) with a sale of 4,660 shares valued at $1,089,741. These trades, although smaller in scale compared to the Tesla and Rocket Lab transactions, are part of ARK's daily portfolio management. Senti Biosciences Inc (NASDAQ:SNTI) also saw a minor reduction, with 163 shares sold for a modest $893. This follows a pattern of selling the biotech stock throughout the previous week. Investors and market analysts closely monitor ARK's daily trades for insights into Cathie Wood's investment strategy. The consistent buying of Tempus AI Inc shares suggests a growing confidence in the company's prospects, while the divestment from Tesla could signal a strategic shift or a simple cashing in on recent gains. As ARK continues to adapt its ETF portfolios, investors will be keen to see how these daily trades align with broader market trends and the investment firm's long-term vision.

Cathie Wood's Ark Invest Trims Tesla Exposure Amid Searing Rally, Sells $21.8M Worth Of Stock -- Bets On This AI Medical Company - ARK Genomic Revolution ETF (BATS:ARKG), ARK Innovation ETF (ARCA:ARKK)

On Wednesday, Cathie Wood-led Ark Invest executed significant trades involving Tesla Inc. TSLA and Tempus AI Inc. TEM. The investment firm opted to sell a substantial number of Tesla shares while increasing its stake in Tempus AI. These trades come amid noteworthy market movements, including Tesla's stock reaching new all-time highs. The Tesla Trade The ARK Innovation ETF ARKK fund sold 51,335 shares of Tesla, valued at approximately $21.8 million, based on the closing price of $424.77. This decision coincides with Tesla's stock reaching a new all-time high, driven by a surge in its price following the 2024 presidential election. Analysts have been raising their price targets for the electric vehicle giant, contributing to its stock hitting a 52-week high of $415. The stock's performance has been buoyed by favorable market conditions, including anticipated interest rate cuts by the Federal Reserve. Elon Musk, Tesla's CEO, has become the first person to surpass a net worth of $400 billion, thanks to the stock's impressive rally. The stock's momentum is expected to continue as market analysts remain optimistic about its future prospects. The Tempus AI Trade In contrast to its Tesla trade, Ark Invest significantly increased its position in Tempus AI, purchasing 424,522 shares through its ARK Genomic Revolution ETF ARKG and ARKK funds. The total value of this acquisition is approximately $18.3 million, calculated using the closing price of $43.19. Tempus AI, a healthcare diagnostics company, has been in the spotlight, partly due to strategic investments from major players like Google and SoftBank. Other Key Trades: Sold shares of Veracyte Inc. from the ARKG fund.Sold shares of Rocket Lab USA Inc. from the ARKQ fund.Bought shares of Symbotic Inc. through the ARKQ fund. Image via Benzinga YouTube and Unsplash Read Next: Gamestop, Adobe, Meta, Candel Therapeutics, And Tesla: Why These 5 Stocks Are On Investors' Radars Today This story was generated using Benzinga Neuro and edited by Shivdeep Dhaliwal Market News and Data brought to you by Benzinga APIs